Form 4 for MLTX MoonLake Immunotherapeutics
Accepted 2025-07-07 00:00:00 ET · period of report 2025-07-03 · accession 0001213900-25-061752 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-07-07 | 2025-07-03 | MLTX | Moukheibir Catherine | Dir | S - Sale+OE | $48.79 | -23.5K | 0 | -100% | -$1.15M |
| D | 2025-07-07 | 2025-07-03 | MLTX | Moukheibir Catherine | Dir | M - OptEx | $0.00 | +23.5K | 23.5K | New | $0 |
| D | 2025-07-07 | 2025-07-03 | MLTX | Moukheibir Catherine | Dir | M - OptEx | $0.00 | -23.5K | 21.5K | -52% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A ordinary shares, par value $0.0001 per share | 2025-07-03 | S | D | 23,500 | $48.79 | 0 | D | — | — | (F1) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $48.59 to $49.01. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| 2 | Common | Class A ordinary shares, par value $0.0001 per share | 2025-07-03 | M | A | 23,500 | $0.00 | 23,500 | D | — | — | |
| 3 | Derivative | Option to Buy | 2025-07-03 | M | D | 23,500 | $0.00 | 21,500 | D | $12.25 · — to 2032-04-06 | 23,500 Class A ordinary shares, par value $0.0001 per share | (F2) These options are fully vested. |